Sign in to view content

FIDO Study: 10-Year Outcomes of Eyes Receiving Continuous, Fixed-Interval Dosing of Anti-VEGF Agents for Neovascular Age-Related Macular Degeneration

Ivan J. Suner, MD, MBA

Video
Published 2019

Ivan J. Suner, MD, MBA

AMD Neovascular Part II Symposium

Related

BiWeekly Anti-VEGF Dosing for Chronic Refractory Neovascular Age-Related Macular Degeneration Unresponsive to Standard Monthly Dosing
Eric W Schneider, MD
Annual Meeting Talks
2019
Vision Threatening Complications in Patients With Diabetic Macular Edema: A Post Hoc Analysis of the VISTA and VIVID Trials
Diana V Do, MD, FASRS
Updates from the Field
2019
Anti-VEGF Injections and Risk of Traction Retinal Detachments in Eyes With Proliferative Diabetic Retinopathy: Pooled Analysis of 5 DRCR.net Trials
Hani Salehi-Had, MD, FASRS
Updates from the Field

Category: AMD-Neovascular

See more